Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorYork Univ-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorYale Univ-
Autor(es): dc.creatorShoukat, Affan-
Autor(es): dc.creatorVilches, Thomas [UNESP]-
Autor(es): dc.creatorMoghadas, Seyed M.-
Data de aceite: dc.date.accessioned2022-02-22T00:04:42Z-
Data de disponibilização: dc.date.available2022-02-22T00:04:42Z-
Data de envio: dc.date.issued2020-12-09-
Data de envio: dc.date.issued2020-12-09-
Data de envio: dc.date.issued2019-11-30-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3201/eid2512.181324-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/195071-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/195071-
Descrição: dc.descriptionZika virus remains a major public health concern because of its association with microcephaly and other neurologic disorders in newborns. A prophylactic vaccine has the potential to reduce disease incidence and eliminate birth defects resulting from prenatal Zika virus infection in future outbreaks. We evaluated the cost-effectiveness of a Zika vaccine candidate, assuming a protection efficacy of 60%-90%, for 18 countries in the Americas affected by the 2015-2017 Zika virus outbreaks. Encapsulating the demographics of these countries in an agent-based model, our results show that vaccinating women of reproductive age would be very cost-effective for sufficiently low (<$16) vaccination costs per recipient, depending on the country-specific Zika attack rate. In all countries studied, the median reduction of microcephaly was >75% with vaccination. These findings indicate that targeted vaccination of women of reproductive age is a noteworthy preventive measure for mitigating the effects of Zika virus infection in future outbreaks.-
Descrição: dc.descriptionNatural Sciences and Engineering Research Council of Canada (NSERC)-
Descrição: dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)-
Descrição: dc.descriptionCanadian Foundation for Innovation (CFI)-
Descrição: dc.descriptionYork Univ, Toronto, ON, Canada-
Descrição: dc.descriptionSao Paulo State Univ, Botucatu, SP, Brazil-
Descrição: dc.descriptionYale Univ, New Haven, CT USA-
Descrição: dc.descriptionSao Paulo State Univ, Botucatu, SP, Brazil-
Descrição: dc.descriptionCAPES: 88881.132327/2016-01-
Formato: dc.format2191-2196-
Idioma: dc.languageen-
Publicador: dc.publisherCenters Disease Control & Prevention-
Relação: dc.relationEmerging Infectious Diseases-
???dc.source???: dc.sourceWeb of Science-
Título: dc.titleCost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.